Clinical Research Directory
Browse clinical research sites, groups, and studies.
Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation
Sponsor: Massimo Falconi
Summary
Non-functioning pancreatic neuroendocrine tumors (NF-PanNETs) are heterogeneous neoplasms of the pancreatic endocrine tissue, displaying variable clinical behavior from indolent to highly aggressive forms. Their often asymptomatic nature and lack of reliable preoperative biomarkers make clinical management particularly challenging. This exploratory study will investigate cell-free DNA (cfDNA) as a potential non-invasive biomarker in NF-PanNETs. cfDNA samples from approximately 30 patients, representing distinct clinical courses (active surveillance, indolent post-surgical, and aggressive post-surgical cases), will be analyzed using advanced methylome and nucleosome footprinting techniques. The aim is to evaluate cfDNA's diagnostic and prognostic potential to improve disease monitoring and support personalized therapeutic strategies in NF-PanNET patients.
Official title: Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation: a Retrospective Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2026-09-12
Completion Date
2027-12-12
Last Updated
2026-09-16
Healthy Volunteers
No
Conditions
Interventions
cfDNA molecular profiling
Circulating-free DNA (cfDNA) will be extracted from plasma samples previously collected and currently stored at the San Raffaele Hospital (HSR) NETBank biobank. cfDNA profiling will be performed using methylome and nucleosome footprinting techniques. No therapeutic or experimental intervention will be performed.
Locations (1)
IRCCS San Raffaele
Milan, MI, Italy